Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Replimune Group, Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 122 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$8.58 - USD$54.85 |
---|---|
50-day moving average | USD$40.6088 |
200-day moving average | USD$36.4733 |
Wall St. target price | USD$56.3 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.014 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -11% |
Return on equity TTM | -21.06% |
Profit margin | 0% |
Book value | $11.129 |
Market capitalisation | USD$1.7 billion |
TTM: trailing 12 months
There are currently 2.5 million Replimune Group shares held short by investors – that's known as Replimune Group's "short interest". This figure is 16.8% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Replimune Group shares can be evaluated.
Replimune Group's "short interest ratio" (SIR) is the quantity of Replimune Group shares currently shorted divided by the average quantity of Replimune Group shares traded daily (recently around 441554.94699647). Replimune Group's SIR currently stands at 5.66. In other words for every 100,000 Replimune Group shares traded daily on the market, roughly 5660 shares are currently held short.
However Replimune Group's short interest can also be evaluated against the total number of Replimune Group shares, or, against the total number of tradable Replimune Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Replimune Group's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Replimune Group shares in existence, roughly 50 shares are currently held short) or 0.1127% of the tradable shares (for every 100,000 tradable Replimune Group shares, roughly 113 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Replimune Group.
Find out more about how you can short Replimune Group stock.
We're not expecting Replimune Group to pay a dividend over the next 12 months.
Over the last 12 months, Replimune Group's shares have ranged in value from as little as $8.58 up to $54.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 2.6296. This would suggest that Replimune Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.